Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of ALPINE IMMUNE SCIENCES, INC. from 31 Dec 2015 to 31 Mar 2024
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
- Summary
-
ALPINE IMMUNE SCIENCES, INC. quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 31 Dec 2015 to 31 Mar 2024.
- ALPINE IMMUNE SCIENCES, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Mar 2024 was $10,905,000, a 1101% decline year-over-year.
- ALPINE IMMUNE SCIENCES, INC. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $30,559,000.
- ALPINE IMMUNE SCIENCES, INC. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was $54,531,000, a 266% decline from 2021.
- ALPINE IMMUNE SCIENCES, INC. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2021 was $32,948,000, a 76% increase from 2020.
- Source SEC data
- View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)
ALPINE IMMUNE SCIENCES, INC. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2024 | $10,905,000 | -$11,994,000 | -1101% | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 09 May 2024 | 2024 | Q1 | |
| Q1 2023 | $1,089,000 | +$34,107,000 | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 09 May 2024 | 2024 | Q1 | ||
| Q1 2022 | $33,018,000 | -$10,688,000 | -48% | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 11 May 2023 | 2023 | Q1 | |
| Q1 2021 | $22,330,000 | -$30,653,000 | -368% | 01 Jan 2021 | 31 Mar 2021 | 10-Q | 12 May 2022 | 2022 | Q1 | |
| Q1 2020 | $8,323,000 | -$22,657,000 | -73% | 01 Jan 2020 | 31 Mar 2020 | 10-Q | 13 May 2021 | 2021 | Q1 | |
| Q1 2019 | $30,980,000 | +$31,534,000 | 01 Jan 2019 | 31 Mar 2019 | 10-Q | 14 May 2020 | 2020 | Q1 | ||
| Q1 2018 | $554,000 | -$2,303,000 | -132% | 01 Jan 2018 | 31 Mar 2018 | 10-Q | 09 May 2019 | 2019 | Q1 | |
| Q1 2017 | $1,749,000 | 01 Jan 2017 | 31 Mar 2017 | 10-Q | 14 May 2018 | 2018 | Q1 |
ALPINE IMMUNE SCIENCES, INC. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2023 | $30,559,000 | +$85,090,000 | 01 Jan 2023 | 31 Dec 2023 | 10-K | 20 Mar 2024 | 2023 | FY | |
| 2022 | $54,531,000 | -$87,479,000 | -266% | 01 Jan 2022 | 31 Dec 2022 | 10-K | 20 Mar 2024 | 2023 | FY |
| 2021 | $32,948,000 | +$14,244,000 | +76% | 01 Jan 2021 | 31 Dec 2021 | 10-K | 20 Mar 2024 | 2023 | FY |
| 2020 | $18,704,000 | +$13,038,000 | +230% | 01 Jan 2020 | 31 Dec 2020 | 10-K | 23 Mar 2023 | 2022 | FY |
| 2019 | $5,666,000 | +$2,955,000 | +109% | 01 Jan 2019 | 31 Dec 2019 | 10-K | 17 Mar 2022 | 2021 | FY |
| 2018 | $2,711,000 | +$6,398,000 | 01 Jan 2018 | 31 Dec 2018 | 10-K | 18 Mar 2021 | 2020 | FY | |
| 2017 | $3,687,000 | -$10,083,000 | -158% | 01 Jan 2017 | 31 Dec 2017 | 10-K | 30 Mar 2020 | 2019 | FY |
| 2016 | $6,396,000 | +$973,000 | +18% | 01 Jan 2016 | 31 Dec 2016 | 10-K | 18 Mar 2019 | 2018 | FY |
| 2015 | $5,423,000 | 01 Jan 2015 | 31 Dec 2015 | 10-K | 28 Mar 2018 | 2017 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.